<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Disease-specific biomarkers should reflect a fundamental feature of neuropathology and be validated in neuropathologically confirmed cases </plain></SENT>
<SENT sid="1" pm="."><plain>Several synaptic proteins have been described in cerebrospinal fluid (CSF) of patients with <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:e sem="disease" ids="C0752347" disease_type="Disease or Syndrome" abbrv="DLB">Lewy body disease</z:e> alpha-synuclein is incorporated within <z:hpo ids='HP_0100315'>Lewy bodies</z:hpo> and alpha-, beta- and gamma-synucleins in dystrophic <z:mp ids='MP_0006082'>neuritis</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>These pathological changes are expected to be seen in CSF </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: A total of 25 CSF post-mortem samples (8 control and 17 subjects with <z:hpo ids='HP_0000726'>dementia</z:hpo>) were used to quantify alpha- and gamma-synucleins and IgG </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: We describe for the first time the presence of gamma-synuclein in CSF </plain></SENT>
<SENT sid="6" pm="."><plain>There is an elevation of both alpha- and gamma-synucleins in CSF from elderly individuals with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e>, <z:e sem="disease" ids="C0752347" disease_type="Disease or Syndrome" abbrv="DLB">Lewy body disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBD</z:e>) and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>), compared to <z:mpath ids='MPATH_458'>normal</z:mpath> controls </plain></SENT>
<SENT sid="7" pm="."><plain>gamma-Synuclein showed a greater elevation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBD</z:e>, IgG in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The elevation of alpha- and gamma-synucleins was seen from Braak stage III onwards and remained stable until Braak stage VI </plain></SENT>
<SENT sid="9" pm="."><plain>These results were not influenced by age at <z:hpo ids='HP_0011420'>death</z:hpo> or post-mortem delay </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: The reported increases in alpha- and gamma-synucleins and IgG in the ventricular CSF of individuals with <z:hpo ids='HP_0000726'>dementia</z:hpo> are novel findings </plain></SENT>
<SENT sid="11" pm="."><plain>They now need to be explored further using a greater number of cases in each subgroup, using lumbar CSF samples to determine their applicability and relevance to a clinical diagnostic setting </plain></SENT>
<SENT sid="12" pm="."><plain>It needs to be established whether using these markers may help to discriminate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBD</z:e> from other types of neurodegenerative and vascular <z:hpo ids='HP_0000726'>dementias</z:hpo> </plain></SENT>
</text></document>